Fixed 1000 IU 4F-PCC: Faster but Statistically Unproven for VKA Reversal

PROPER3 tests whether a single fixed 1000 IU dose of 4-factor prothrombin complex concentrate can replace weight- and INR-based variable dosing for extracranial VKA bleeding, and finds comparable hemostasis with faster delivery but no formal proof of noninferiority.

prothrombin complex concentrate4F-PCCCofactBeriplexKcentravitamin K antagonistacenocoumarolphenprocoumonwarfarinanticoagulation reversalextracranial bleedingINRrandomized controlled trialnoninferiority Anticoagulation

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Abdoellakhan RA, Khorsand N, Ter Avest E, Lameijer H, Faber LM, Ypma PF, Nieuwenhuizen L, Veeger NJGM, Meijer K

Citation: Abdoellakhan RA, Khorsand N, Ter Avest E, et al. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial. Annals of emergency medicine. 2022;79(1):20-30. doi:10.1016/j.annemergmed.2021.06.016

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Full deep analysis for this article is still in progress. Check back soon.